Drug intelligence / Profile preview

SPC3

Development stage: Phase 1
Lead developer: Columbia Research Laboratories
Modality: Peptides
Administration: Intravenous

Overview

SPC3 is a synthetic peptide construction under investigation for its potential to treat HIV-1 infection. It is being studied for its effects on HIV-1 plasma levels and lymphocyte subsets in HIV-1 seropositive patients with an initial viral load above 10,000 copies/ml. The drug's safety and the kinetics of HIV-1 plasma level changes are also being assessed.

Other names: synthetic peptide construction 3

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on SPC3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPC3.

Explore the full profile